Main Article Content
bronchial endoscopy, children, eosinophils, mepolizumab, severe asthma
Background: Asthma is characterized by a chronic airway inflammation, usually sustained by type 2 immunity. Bronchial and peripheral eosinophilia are biomarkers for type 2 asthma. Biologicals are the most effective treatment for severe asthma at present. Mepolizumab is an antagonist of interleukin-5 (IL-5), the most relevant cytokine involved in eosinophilia.
Objective: This case report evaluated the effectiveness of mepolizumab in two girls with severe eosinophilic non-allergic asthma.
Materials and methods: Two female children with severe eosinophilic nonallergic asthma were treated with mepolizumab for two years. Clinical findings, lung function, peripheral eosinophils, asthma control, and bronchial endoscopy were performed.
Results: Biologicals reduced the eosinophilia, asthma exacerbations, and improved lung function in both patients. The treatment was also safe and well-tolerated.
Conclusion: Mepolizumab represents an effective therapeutic option in the management of severe pediatric asthma.
2. Pavlidis S, Takahashi K, NgKeeKwong F, Xie J, Hoda U, Sun K, et al. “T2-high” in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin. Eur Respir J. 2019;53:1800938. https://doi.org/10.1183/13993003.00938-2018
3. Price DB, Rigazio A, Campbell JD, Bleacker ER, Corrigan CJ, Thomas M, et al. Blood eosinophils count and prospective annual asthma disease burden: A UK cohort study. Lancet Respir Med. 2015;3(11):849–58. https://doi.org/10.1016/S2213-2600(15)00367-7
4. Mukherjee M, Nair P. Blood or sputum eosinophils to guide asthma therapy? Lancet Respir Med. 2015;3(11):824–5. https://doi.org/10.1016/S2213-2600(15)00419-1
5. de Blic J, Midulla F, Barbato A, Clement A, Dab I, Eber E, et al. Bronchoalveolar lavage in children. ERS Task Force on bronchoalveolar lavage in children. European Respiratory Society. Eur Respir J. 2000;15(1):217–31. https://doi.org/10.1183/090319 36.00.15121700
6. Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, et al., After asthma: Redefining airways dis-eases. Lancet. 2018;391:350–400. https://doi.org/10.1016/ S0140-6736(17)30879-6
7. Nadif R, Sioux V, Boudier A, le Moual N, Just J, Gormand F, et al. Blood granulocyte patterns as predictors of asthma phenotypes in adults from the EGEA study. Eur Respir J 2016;48(4):1040–1051. https://doi.org/10.1183/13993003.00336-2016
8. Duncan EM, Fahy JV. Asthma and corticosteroids: Time for a more precise approach to treatment. Eur Respir J. 2017;49:1701167. https://doi.org/10.1183/13993003.01167-2017
9. Kavanagh JE, d’Ancona G, Elstad M, Green L, Fernandes M, Roxas C, et al. Real-world effectiveness and the characteristics of a ‘super-responder’ to mepolizumab in severe eosinophilic asthma. Chest. 2020;158:491–500 https://doi.org/10.1016/j.chest.2020.03.042
10. Stein ML, Villanueva JM, Buckmeier BK, Yamada Y, Filipovich AH, Assa’ad AH, et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol. 2008;121:1473–83. https://doi.org/10.1016/j.jaci.2008.02.033
11. Gupta A, Pouliquen I, Austin D, Price RG, Kempsford R, Steinfeld J, et al. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Ped Pulmonol. 2019;54:1957–67. https://doi.org/10.1002/ppul.24508
12. Gupta A, Ikeda M, Geng B, Azmi J, Price RG, Bradford ES, et al. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol. 2019;144:1336–42. https://doi.org/10.1016/j.jaci.2019.08.005
13. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2021 [Internet]. [cited 2016 Sep 5] Available from: www.ginasthma.org (last access 06/26/2021)
14. Andrew B. Which child with asthma is a candidate for biological therapies? J Clin Med. 2020;9(4):1237. https://doi.org/10.3390/jcm9041237